Presentations

  1. Total Synthesis of Marasmic Acid, Temple University, October 12, 1980.
  2. Total Synthesis of Marasmic Acid, University of Maryland, February 3, 1981.
  3. The Synthesis of Unusual Amino Acids as Enzyme Inhibitors, State University of New York at Stony Brook, April 25, 1985.
  4. The Synthesis of Unusual Amino Acids as Enzyme Inhibitors, University of Iowa, June 7, 1985.
  5. Design of Inhibitors of Human Renin, Center for Biotechnology, State University of New York at Stony Brook, May 3, 1989.
  6. Design of Inhibitors of Human Renin, McGill University, November 7, 1990.
  7. Design and Synthesis of Orally-Active Nonpeptide Angiotensin II Antagonists, Gordon Research Conference on Medicinal Chemistry, New London, NH, August 5-9, 1991.
  8. Design of Human Renin Inhibitors, DuPont Merck Pharamceutical Company, May 1, 1992.
  9. Design and Synthesis of a New Class of Orally-Active Angiotensin II Antagonists, Royal Society of Chemistry Fine Chemicals and Medicinals Group, meeting on “Recent Advances in Drugs for the Treatment of Cardiovascular Disease, Glasgow, Scotland, October 14-15, 1992.
  10. Design and Synthesis of a AT1-Selective and “Balanced (AT1/AT2) Nonpeptidic Angiotensin II Antagonists, IBC Conference on New Advances in Peptidomimetics & Small Molecule Design for Drug Development, Doubletree Hotel, Philadelphia, PA, March 23-25, 1994.
  11. Design and Synthesis of AT1-Selective and Balanced Angiotensin II Antagonists, West Coast Biotechnology Meeting, San Diego, CA, October 14-17, 1995.
  12. Antihypertensives: Recent Advances in Development of Blockers of the Renin-Angiotensin System, XIVth International Symposium on Medicinal Chemistry, Maastrict, Holland, September 8-12, 1996.
  13. Muscarinic Agonists and Antagonists in the Treatment of Alzheimer’s Disease, XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, September 18-22, 2000.
  14. Discovery of Muscarinic M2 Receptor Antagonists for the Treatment of Alzheimer’s Disease and CCR5 Receptor Antagonists for the Treatment of HIV Infection, University Of Minnesota, Departement of Medicinal Chemistry, April 22, 2003.
  15. Design and Synthesis of Thrombin Receptor Antagonists, Alfred Burger Award Address, 229th American Chemical Society National Meeting, San Diego, CA, March 13-17th, 2005.
  16. Design and Synthesis of Thrombin Receptor Antagonists, State University of New York at Stony Brook, Department of Chemistry, April 22, 2005.
  17. Design and Synthesis of Thrombin Receptor Antagonists, 9th Beijing Healthcare Industry Forum, Beijing International Conference Center, Beijing, China, October 20, 2005.
  18. Design and Synthesis of Thrombin Receptor Antagonists, Shanghai Institute of Organic Chemistry, Shanghai, China, October 25, 2005.
  19. Design and Synthesis of Thrombin Receptor Antagonists, American Chemical Society Mid-Atlantic Regional Meeting (MARM), Hershey, PA, June 4-7, 2006.
  20. Design and Synthesis of Thrombin Receptor Antagonists, 21st Annual William S. Johnson Symposium, Stanford University, Palo Alto, CA, October 14-15, 2006.
  21. Design and Synthesis of Thrombin Receptor Antagonists,.” Neurocrine Biosciences, San Diego, CA, October 17, 2006.
  22. Design and Synthesis of Thrombin Receptor Antagonists, Advances in Chemical Sciences Symposium – sponsored by NESACS, IUPAC and RSC-US, Royal Sonesta Hotel, Cambridge, MA, March 30, 2007.
  23. Design and Synthesis of Thrombin Receptor Antagonists, Wayne State University, Detroit, MI, April 25, 2007.
  24. Design and Synthesis of Thrombin Receptor Antagonists, Zhengzhou University, Zhengzhou, China, June 30, 2007.
  25. Design and Synthesis of Thrombin Receptor Antagonists, SAPA China Pharmaceutical and Biotechnology Conference, Galaxy Hotel, Shanghai, China, July, 3-5, 2007.
  26. Design and Synthesis of Thrombin Receptor Antagonists, WuXi Pharmatech, Shanghai, China, July 6, 2007
  27. Design and Synthesis of Thrombin Receptor Antagonists, Advances in Synthetic and Medicinal Chemistry (ASMC2007), St. Petersburg, Russia, August 28 – September 2, 2007.
  28. Design and Synthesis of Thrombin Receptor Antagonists, Northwestern University, Evanston, Illinois, October 31, 2007.
  29. Design and Synthesis of Thrombin Receptor Antagonists, AMRI Drug Discovery Symposium, Desmond Hotel, Albany, NY, October 15-16, 2008.
  30. Design and Synthesis of Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis, Bristol-Myers Squibb Smissman Symposium, 237th American Chemical Society National Meeting, Salt Lake City, UT, March 22-26, 2009.
  31. Discovery of Drug Candidates at Schering-Plough: Case Histories from Cardiovascular and CNS Therapy Areas, ACS ProSpectives Conferences on the Discovery, Development & Production of Pharmaceuticals and Therapeutics, Discovery & Selection of Successful Drug Candidates with special emphasis on Structure-Based Drug Design, The Hyatt Regency, Cambridge, MA, April 26 – 29, 2009.
  32. Discovery of Drug Candidates at Schering-Plough: Case Histories from Cardiovascular and CNS Therapy Areas, Institute of Chemical Biology and Drug Discovery (ICB&DD) Symposium, “Frontiers in Chemical Biology and Drug Discovery,” Stony Brook University, Stony Brook, NY, October 6, 2009.
  33. Natural Products as Leads for Small Molecule Drug Discovery: The Discovery of Thrombin Receptor Antagonists Based on the Natural Product Himbacine, Visions in Chemistry Symposium, The Knud Lind Larsen Program, Danish Academy of Technical Sciences, Copenhagen, Denmark, 29-30 January 2010.
  34. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Discovery of Vorapaxar, Cecil Pickett Retirement Symposium, Merck Research Laboratories, Kenilworth, NJ, September 30, 2010.
  35. Discovery of Drug Candidates for the Treatment of Parkinson’s Disease and Alzheimer’s Disease, Department Symposium, Stevens Institute, Hoboken, NJ, October 20, 2010.
  36. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Discovery of Vorapaxar, Rahway Connectivity DPS Symposium, Merck Research Laboratories, Rahway, NJ, October 22, 2010.
  37. Discovery of Drug Candidates for the Treatment of Parkinson’s Disease and Alzheimer’s Disease, Department Symposium, Stony Brook University, Stony Brook, NY, November 29, 2010.
  38. Discovery of Drug Candidates for the Treatment of Parkinson’s Disease and Alzheimer’s Disease, Pennsylvania Drug Discovery Institute, Philadelphia, PA, November 29, 2011.
  39. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, Abbott Laboratories, North Chicago, IL, March 7, 2012. 
  40. Medicinal Chemistry Consulting – Challenges and Rewards, Lunch and Learn presentation for the Division of Medicinal Chemistry, ACS National Meeting, San Diego, CA, March 25-19, 2012.
  41. Small Molecule and Biologic Drug Discovery and Development, Pharm Fest, Montclair University, April 3, 2012. 
  42. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, Gilead Sciences, Foster City, CA, April 26, 2012.
  43. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, EnVivo Pharmaceuticals, Watertown, MA, May 15, 2012.
  44. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, Venenum Biodesign, Hamilton, NJ, July 11, 2012.
  45. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, Paraza Pharma, Laval, Quebec, July 25, 2012.
  46. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Case History of Vorapaxar, Medicinal Chemistry India 2013, Chennai, India, February 14, 2013.
  47. Discovery of Drug Candidates for the Treatment of Parkinson’s  Disease and Alzheimer’s Disease, TCG Life Sciences, Kolkata, India, February 18, 2013.
  48. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Case History of Vorapaxar, AbbVie Medicinal Chemistry Summit, Independence Grove, Libertyville, IL, November 7, 2013.
  49. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Case History of Vorapaxar, Paraza Pharma, Montreal, Quebec, July 29, 2014.
  50. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Case History of Vorapaxar, International Symposium of Chemistry and Life Sciences, Jiangyin International Hotel, Jiangyin, PRC, October 16-17, 2014.
  51. Thrombin Receptor Antagonists for the Prevention of Arterial Thrombosis – Case History of Vorapaxar, CHE607 Modern Drug Discovery Course, Stony Brook University, Stony Brook, NY, December 1, 2014.
  52. Thrombin receptor antagonists for the prevention of arterial thrombosis: Discovery of vorapaxar (ZontivityTM), UCB Pharma, Slough, England, March 10, 2015.
  53. Thrombin receptor antagonists for the prevention of arterial thrombosis: Discovery of vorapaxar (ZontivityTM), 249th ACS National Meeting, Denver, CO, March 24, 2015.
  54. Thrombin receptor antagonists for the prevention of arterial thrombosis: Case History of vorapaxar (ZontivityTM), Virginia Commonwealth University, Richmond, VA, October 8, 2015.
  55. Thrombin receptor antagonists for the prevention of arterial thrombosis: Case History of vorapaxar (ZontivityTM), Genentech, South San Francisco, CA, January 12, 2016.
  56. Designing Drugs for Optimal Brain Penetration, CHE607 Modern Drug Discovery Course, Stony Brook University, Stony Brook, NY, November 28, 2017.